Draig Therapeutics Ltd

Quick facts

Phase 2 pipeline

• DT-101 · Oncology
  DT-101 is a small molecule that targets the CDK4/6 pathway.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Draig Therapeutics Ltd portfolio CI brief
• Draig Therapeutics Ltd pipeline updates RSS